Abstract
CVS Health will report second-quarter 2026 results on August 05, 2026, Pre-Market; this preview outlines consensus forecasts, last quarter’s performance, segment dynamics, and the dominant analyst stance ahead of the print.Market Forecast
Based on the company’s latest guidance framework and market estimates, consensus for the current quarter points to revenue of 100.11 billion US dollars, adjusted EPS of 1.85, and EBIT of 3.94 billion US dollars, implying year-over-year growth of 5.94%, 27.08%, and 21.91%, respectively. Forecast commentary indicates modest gross profit expansion from mix tailwinds and a slight improvement in net profitability; estimate-based YoY growth implies incremental margin lift, though explicit gross margin and net margin forecasts are not provided.CVS Health’s main business is diversified across Health Services, Health Care Benefits, and Pharmacy and Consumer Health, with Health Services expected to remain the largest revenue contributor driven by pharmacy benefit management volume and maintenance care trends. The most promising segment in the near term is Health Services, supported by prescription growth and optimized purchasing following recent retail footprint and purchasing initiatives; current-quarter growth is projected to be primarily volume-led with stable contract economics.
Last Quarter Review
In the prior quarter, CVS Health delivered revenue of 100.43 billion US dollars, a gross profit margin of 15.07%, GAAP net profit attributable to shareholders of 2.94 billion US dollars, a net profit margin of 2.95%, and adjusted EPS of 2.57, with revenue up 6.17% year over year and adjusted EPS up 14.22% year over year.A key business highlight was broad-based revenue outperformance versus estimates across the enterprise, with an EBIT beat and solid adjusted EPS leverage, reflecting execution in pharmacy benefit operations and retail script growth. Main business highlights showed Health Services at 48.24 billion US dollars, Health Care Benefits at 35.97 billion US dollars, and Pharmacy and Consumer Health at 31.99 billion US dollars, offset by 15.90 billion US dollars of eliminations; volume and integration benefits in Health Services accounted for the largest contribution to the quarter’s growth.
Current Quarter Outlook
Main business trajectory
Health Services remains the operational anchor for revenue and earnings this quarter, supported by steady utilization trends in maintenance medications and continued wins and retention in pharmacy benefit management. Volume tailwinds, including higher scripts and specialty penetration, should support top-line growth while procurement and network optimization help defend gross margin. Management’s recent focus on operating discipline and cost controls in fulfillment and care delivery is expected to partially offset reimbursement pressure and generic deflation. Pricing resets remain manageable under multi-year contracts, suggesting incremental stability through the quarter.Most promising growth engine
The most promising near-term engine is Health Services, where prescription volume, specialty therapies, and service breadth continue to scale. The integration of recent retail assets has reinforced purchasing power and enhanced the front-end attachment rate for chronic patients, feeding PBM and specialty flows. While per-script margins are structurally thin industry-wide, the volume run-rate and mix into higher-value therapies support EBIT growth above revenue growth, consistent with the estimate trajectory for the quarter. Continued digital engagement and adherence programs strengthen retention, which tends to compound in the second half of the year as plan members stabilize post-cycle.Key stock-price swing factors this quarter
The first swing factor is medical cost trend within Health Care Benefits, particularly Medicare Advantage utilization and policy updates that influence medical loss ratios; modest improvements versus last year’s late-year pressure would be supportive to consolidated margin. The second is retail execution in Pharmacy and Consumer Health, where front-store rationalization and script growth must be balanced against pricing investments; favorable front-end mix could modestly lift gross profit. The third is PBM client activity and specialty pipeline dynamics; incremental wins or better-than-expected specialty uptake would bolster revenue and EBIT, while any contract repricing noise could weigh on sentiment.Analyst Opinions
Across recent institutional commentary, the majority view is bullish. Notable positive stances include Goldman Sachs maintaining Buy with a 116.00 US dollars price target, Mizuho Securities reiterating Buy with targets cited at 102.00–120.00 US dollars in recent notes, Wells Fargo maintaining Buy with a 103.00 US dollars target, Bernstein reiterating Buy with a 106.00 US dollars target, and RBC Capital reiterating Buy with a 107.00 US dollars target. These bullish views outnumber neutral or absent U.S.-focused views in the period, indicating a favorable skew ahead of the quarter.The bullish camp emphasizes three points. First, execution momentum from the last quarter’s revenue and EPS beats suggests operational follow-through, especially in Health Services where volume, specialty mix, and contracting remain constructive. Second, consensus modeling shows double-digit year-over-year growth in EBIT and adjusted EPS for the current quarter, implying incremental operating leverage and improving margin quality, a dynamic analysts argue is underappreciated in valuation. Third, analysts expect stabilization in medical cost trend within Health Care Benefits relative to peak pressures, which could limit downside volatility and support full-year EPS cadence.
Goldman Sachs highlights the potential for specialty pipeline strength and durable PBM retention to sustain mid-single-digit revenue growth with better-than-expected flow-through as procurement and network initiatives mature. Mizuho points to improving visibility around full-year adjusted EPS and sees catalysts in cost control and retail optimization that safeguard gross margin, even if reimbursement headwinds persist. Wells Fargo and RBC Capital note that the company’s balanced portfolio offers defensive earnings characteristics while still enabling growth in high-need therapeutic areas; they frame the risk-reward as favorable into the print given consensus already contemplates conservative medical cost assumptions. Bernstein underscores that estimate revisions have begun to trend upward and that the current-quarter EPS setup leaves room for constructive surprises if volume mix or cost containment outperform.
Overall, the dominant institutional stance is that CVS Health enters this quarter with a credible pathway to meet or slightly exceed revenue and EPS expectations, anchored by Health Services volume and a gradually normalizing medical cost environment. The constructive skew is reinforced by the last quarter’s delivery against expectations and by the model-implied step-up in EBIT and EPS growth this quarter.